Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2082981 | PMC |
| http://dx.doi.org/10.1136/adc.2006.103333 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The current clinical practice and experiences in buccal midazolam prescribing in community for status epilepticus termination in the United Kingdom: The Rescue Epilepsy Medication and Training (REMIT) study.
Seizure
January 2025
Peninsula School of medicine, University of Plymouth, Truro, United Kingdom; The Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom. Electronic address:
Background: Epilepsy is one of the commonest neurological conditions worldwide and confers a significant mortality risk, partly driven by status epilepticus (SE). Terminating SE is the goal of pharmaceutical rescue therapies. This survey evaluates UK-based healthcare professionals' clinical practice and experience in community-based rescue therapy prescribing.
View Article and Find Full Text PDFUse of benzodiazepines in patients with status epilepticus requiring second-line antiseizure medication treatment.
Epilepsy Res
January 2025
Department of Neurology, Vaasa Central Hospital, Vaasa, Finland.
Background: Status epilepticus (SE) is a life-threatening state that needs rapid and adequate treatment. Benzodiazepines (BZD) are used as a first-line treatment for SE, and if the desired effect is not achieved, second-line antiseizure medications are used.
Objective: To investigate whether the treatment with BZDs is performed adequately in patients with different subtypes of SE requiring second-line ASM treatment and, if not, to identify the factors influencing the suboptimal treatment.
Japanese guidelines for treatment of pediatric status epilepticus - 2023.
Brain Dev
December 2024
Working Group for the Revision of Treatment Guidelines for Pediatric Status Epilepticus/Convulsive Status Epilepticus, Japanese Society of Child Neurology, Tokyo, Japan; Committee for Integration of Guidelines, Japanese Society of Child Neurology, Tokyo, Japan; Division of Child Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan.
Article Synopsis
- The 2015 updated definition of status epilepticus (SE) emphasizes the importance of early treatment, identifying key time points for diagnosis and management.
- Japan has revised its pediatric SE treatment guidelines, recommending buccal midazolam for pre-hospital and in-hospital treatment when intravenous access is not possible, while benzodiazepines are preferred when intravenous access is available.
- The updated guidelines note similarities in seizure cessation rates across different medications, highlight the need for further recommendations on nonconvulsive status epilepticus (NCSE), and plan to explore the effects of NCSE treatment on children's outcomes in future editions.
A practical program for responding to epileptic seizures including buccal midazolam administration in schools: Effectiveness evaluation for Yogo teachers in Japan.
Epilepsy Behav
November 2024
Faculty of Nursing and Medical Care, Keio University, Tokyo, Japan. Electronic address:
Early response to epileptic seizures is critical. In children, epileptic seizures can occur at school, and practical programs are required to enable teachers to respond. In Japan, schoolteachers may administer buccal midazolam orally under certain conditions; however, there are no established training programs for responding to epileptic seizures in schools.
View Article and Find Full Text PDFEfficacy and safety of buccal midazolam for seizures outside the hospital: Real-world clinical experience.
Brain Dev
November 2024
Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Article Synopsis
- Buccal midazolam (buc MDL) is the first medication used in Japan for treating status epilepticus through buccal mucosal delivery, and this study looks at its effectiveness and side effects in real-world cases.* -
- The study reviewed medical records of 26 children treated with buc MDL before arriving at the emergency department from April 2021 to November 2023, finding a 43% efficacy rate in stopping seizures within 10 minutes of administration.* -
- The results suggested that administering buc MDL within the first 15 minutes of a seizure significantly improved outcomes without respiratory complications, and smaller doses within a certain range were still effective.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!